Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Centivax

Request full access

A healthcare-based agency that provides biotechnology, pharmaceutical, medical device manufacturing, and therapeutic services

South San Francisco, United StatesFounded 2020Biotech & Life Sciences

About Centivax

Centivax is a biotechnology startup focused on developing broad-spectrum vaccines, particularly targeting influenza. The company is currently in the pre-clinical development phase, testing its influenza vaccine in ferrets and pigs. This innovative approach has garnered significant attention, including an award from the Gates Foundation's Grand Challenge to End the Pandemic Threat. Additionally, Centivax was featured in the Netflix docuseries "Pandemic: How to Prevent an Outbreak," highlighting its potential impact on global health.

Centivax primarily serves the healthcare sector, including pharmaceutical companies, healthcare providers, and potentially government health agencies. The market it operates in is the global vaccine market, which is crucial for preventing infectious diseases and is valued at billions of dollars annually.

The business model of Centivax revolves around research and development (R&D) of vaccines, securing funding through grants and partnerships, and eventually licensing their vaccine technology to larger pharmaceutical companies. This model allows them to focus on innovation while leveraging the distribution and marketing capabilities of established players in the pharmaceutical industry.

Centivax makes money through a combination of grant funding, such as the one received from the Gates Foundation, and future licensing deals. Once their vaccines are proven effective and safe through clinical trials, they can license the technology to pharmaceutical companies, earning revenue through upfront payments, milestone payments, and royalties on sales.

In summary, Centivax is a promising biotech startup with a focus on developing broad-spectrum vaccines to combat influenza and other infectious diseases. Their innovative approach and strategic partnerships position them well in the competitive global vaccine market.

Source: Dealroom company data

At a glance

Status
Operational
Employees
36
Open positions
1
Dealroom signal
89.9/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotechnology, Synthetic Biology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Mar 2026 $37M $225M John Collison · Patrick Collison · Sigmas Group · Meiji Seika Pharma ↗
SERIES AOther financing Jul 2025 $45M $180M Amplify Partners · NFX · Bold Capital Partners · Kendall Capital Partners ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Centivax website traffic

Latest recorded traffic for Centivax is 5.4K monthly website visits, down 21.7% over the last three months. Centivax's team grew 12.5% over the past year.

Latest monthly visits5.4K 3-month web change-21.7% 1-year team growth+12.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Centivax in the South San Francisco ecosystem

Live from Dealroom

The Centivax office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Henry M. Jackson Foundation
  • Global Health Investment Corporation
  • NFX

Series A10 investors entered at this stage

  • Steve Jurvetson
  • Amplify Partners
  • Bold Capital Partners
  • Kendall Capital Partners
  • Base4 Capital
  • Structure Fund
  • John Collison
  • Patrick Collison
  • Sigmas Group
  • Meiji Seika Pharma
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Centivax’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.